NasdaqGS:PCVXBiotechs
How Investors May Respond To Vaxcyte (PCVX) Raising $550 Million To Fund Pneumococcal Vaccine Pipeline
Vaxcyte, Inc. recently completed a follow-on equity offering of approximately US$550,000,000, issuing 11,000,000 common shares at US$50 each, alongside filing to offer additional common stock and pre-funded warrants.
This capital raise expands Vaxcyte’s financial resources as it advances its VAX-24 and VAX-31 pneumococcal vaccine candidates through clinical development.
We’ll now examine how this sizeable equity raise, and the added financial flexibility it provides, could influence...